Immuno-Oncology | Specialty

Dr. Burris on the Impact of the ASCO Annual Meeting

May 28th 2015

Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

As FDA Considers Approval, Weber Discusses Adjuvant Ipilimumab in Melanoma

May 26th 2015

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

Checkpoint Inhibitors Shine Across Tumor Types at AACR

May 26th 2015

Immune checkpoint blockade strategies were a central focus of much of the key data presented at AACR.

Managing Checkpoint Agents' Immune-Related Toxicities

May 20th 2015

As immunotherapy agents enter into greater clinical use in oncology, clinicians are learning to manage immune-related adverse events related to the mechanism of action of these new drugs.

Optimization of Melanoma Treatment Advances Remains a Work in Progress

May 19th 2015

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

Pembrolizumab Active in Advanced Urothelial Cancer

May 19th 2015

A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Beresford Discusses Using VeriStrat With Immunotherapies

May 12th 2015

Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

Dr. Kenneth Anderson on Combining Immunotherapies in Myeloma

May 6th 2015

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

Clinical Development of Prostate Cancer Vaccines Continues

May 6th 2015

The field of prostate cancer vaccines remains an area of active exploration, with clinical trials into sipuleucel-T continuing even amid a corporate restructuring and a phase III study into PROSTVAC reaching full enrollment.

Sequencing and Timing: Unanswered Questions in Melanoma

May 2nd 2015

CHECKMATE-069: Spectacular Results With Combination Therapy

May 2nd 2015